Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 8/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978845 | 0.90 | HDAC1 (0.52) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2965905 | 0.87 | HDAC1 (0.65) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2979006 | 0.86 | BAZ2B (0.55) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2975642 | 0.86 | HDAC1 (0.49) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2981233 | 0.85 | HDAC6 (0.51) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2980392 | 0.85 | BAZ2B (0.54) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2978179 | 0.85 | HDAC1 (0.65) | HDAC1HDAC6BAZ2BCFTR | |
| SCHEMBL2963961 | 0.85 | BAZ2B (0.54) | HDAC1HDAC6POLBGAAHDAC8 | |
| SCHEMBL2975835 | 0.85 | BAZ2B (0.58) | HDAC1HDAC6HDAC8BAZ2BCFTR | |
| SCHEMBL2971775 | 0.84 | HDAC1 (0.48) | HDAC1HDAC6POLBGAAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | claimed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC6 11/4885POLB 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.